Company News

GOLDEN, Colo. — May 19, 2026 — A growing emphasis on dose-sparing strategies and equitable vaccine access has renewed global interest in ID vaccine delivery. A recent, peer-reviewed publication in Qeios¹ evaluated the evidence on implementation of novel technologies for ID delivery of fractional-dose inactivated polio vaccine (fIPV).

GOLDEN, Colo. — March 24, 2026 — PharmaJet®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network (REDE-TB), plans to initiate a clinical study to evaluate the accuracy, workflow efficiency, safety, and acceptability of the tuberculin

GOLDEN, Colo. — November 4, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, November 9-13, at the Metro Toronto Convention Centre in Toronto, Ontario,

GOLDEN, Colo. — October 21, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its needle-free injection technology, will present at the 15th Annual Partnership Opportunities in Drug Delivery (PODD) conference, October 27-28, at Westin Copley Place in Boston, Massachusetts. The conference brings

GOLDEN, Colo., CAIRO, Egypt — July 10, 2025 — PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma,